Proscia’s Chief Strategy Officer Nathan Buchbinder offers commentary on the findings of recent research conducted by Atheneum on Proscia’s behalf. It found that 70% of major pharmaceutical companies and CROs surveyed currently use digital pathology, and 82% of users have implemented AI.
The top reasons for going digital include improving collaboration and operations (cited by 83%) and getting new drugs to market faster (80%).
“The life sciences community has validated the technology and, in many cases, expanded the use cases, technical capacity, and value propositions of digital pathology. This serves as fodder to fuel clinical adoption,” according to Buchbinder.